Previous 10 | Next 10 |
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases...
DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference on June 6 th at 10:30 AM ET in New...
The following slide deck was published by Prothena Corporation plc in conjunction with this Read more ...
Prothena (NASDAQ: PRTA ): Q1 GAAP EPS of -$0.52 beats by $0.10 . More news on: Prothena Corporation plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline Initiated cell line development of a lead candidate for preclinical tau progra...
DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets. Consistent with past practice, th...
Results from final analysis of the composite primary endpoint were consistent with the futility analysis reported in April 2018 Results from post hoc analyses revealed a potential survival benefit with NEOD001 in the category of patients at the highest risk for early mortality (Mayo Stage...
The following slide deck was published by Prothena Corporation plc in conjunction with this Read more ...
DUBLIN, Ireland, March 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the following March investor conferences: Barclays Global ...
Prothena Corporation PLC (PRTA) Q4 2018 Earnings Conference Call February 14, 2019, 16:30 ET Company Participants Ellen Rose - Head, Communications Gene Kinney - President, CEO & Director Radhika Tripuraneni - Chief Development Officer Wagner Zago - Chief Scientific Officer...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...